Pritelivir
- Generic Name
- Pritelivir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18N4O3S2
- CAS Number
- 348086-71-5
- Unique Ingredient Identifier
- 07HQ1TJ4JE
- Background
Pritelivir has been used in trials studying the prevention of HSV-2 and Genital Herpes.
- Associated Conditions
- -
- Associated Therapies
- -
Aicuris Appoints Jacques Dumas as Chief Scientific Officer
Aicuris appointed Jacques Dumas, Ph.D., as CSO, effective January 1, 2025. With over 30 years in pharmaceutical R&D, Dumas will lead Aicuris’ R&D efforts, focusing on advancing pritelivir for acyclovir-resistant HSV infections and other pipeline programs, aiming to impact patient care significantly.
AiCuris Appoints Dr. Jacques Dumas as CSO, Initiates Phase 1 Trial for AIC468, Appoints Dr. Cynthia Wat as CMO, Announces Pipeline Milestones, Presents AIC468 Data at Conferences, and Collaborates with DZIF for Novel Therapies
Aicuris appoints Dr. Jacques Dumas as CSO, initiates Phase 1 trial for AIC468, appoints Dr. Cynthia Wat as CMO, announces pipeline milestones, presents AIC468 data at conferences, and collaborates with DZIF for novel therapies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath